EQ vs NRIX
EQ: A clinical-stage biotechnology company developing novel aryl hydrocarbon receptor (AhR) modulators for autoimmune and inflammatory diseases. NRIX: Clinical-stage biotech pioneering AI-powered targeted protein degradation medicines for cancer and autoimmune diseases, with Phase 2 lead candidate bexobrutideg in CLL and partnerships spanning Roche, Gilead, and Sanofi.
Side-by-side fundamentals
| Metric | EQ | NRIX | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $2.76 | $23.60 | |
| Market cap as of 2026-07-23 | $174M | $2.4B | |
| PEG as of 2026-07-23 | n/a | -0.21 | |
| Net margin as of 2026-07-23 | -19.6% | -928.4% | EQ higher |
| Operating margin as of 2026-07-23 | -20.1% | -982.4% | EQ higher |
| ROE as of 2026-07-23 | -61.4% | -76.1% | EQ higher |
| ROA as of 2026-07-23 | -53.7% | -57.3% | EQ higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.00 | Tie |
| Revenue growth (YoY) as of 2026-07-23 | n/a | -58.4% | |
| Revenue CAGR (3y) SEC XBRL | +61.5% | +29.5% | EQ higher |
| Dividend streak (yrs) SEC XBRL | n/a | 0 | |
| Beta as of 2026-07-23 | 1.85 | 1.77 | |
| 1-year return as of 2026-07-22 close | +541.5% | +108.7% | EQ higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.